APO Research
Talk to an analyst

APO RESEARCH · REPORT

Candida Infection Testing

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Candida Infection Testing Market Outlook and Growth Opportunities 2026

3 May 2026192 pages

Choose your research edition.

Industry ResearchCandida Infection Testing Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Candida Infection Testing Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Candida Infection Testing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Candida Infection Testing Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Candida Infection Testing Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Candida Infection Testing market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Candida Infection Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Candida Infection Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Candida Infection Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Candida Infection Testing market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Candida Infection Testing market include Roche Diagnostics, Abbott Diagnostics, bioMérieux, Becton Dickinson, Thermo Fisher Scientific, Siemens Healthineers, Bruker, Danaher and QuidelOrtho, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Candida Infection Testing market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Candida Infection Testing and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Candida Infection Testing revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Candida Infection Testing market.

Candida Infection Testing Segment by Company

Roche Diagnostics

Abbott Diagnostics

bioMérieux

Becton Dickinson

Thermo Fisher Scientific

Siemens Healthineers

Bruker

Danaher

QuidelOrtho

Luminex

Hologic

Sysmex

Bio‑Rad Laboratories

Cepheid

Qiagen

ARUP Laboratories

Labcorp

Quest Diagnostics

Eurofins Scientific

Synlab

Candida Infection Testing Segment by Type

Traditional Culture

Molecular Biology Detection

Candida Infection Testing Segment by Application

Medical

Maternal and Child Health

Physical Examination

Aesthetic Medicine

Other

Candida Infection Testing Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Candida Infection Testing status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Candida Infection Testing key companies, revenue, market share, and recent developments.

3. To split the Candida Infection Testing breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Candida Infection Testing market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Candida Infection Testing significant trends, drivers, influence factors in global and regions.

6. To analyze Candida Infection Testing competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Candida Infection Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Candida Infection Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Candida Infection Testing.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Candida Infection Testing industry.

Chapter 3: Detailed analysis of Candida Infection Testing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Candida Infection Testing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Candida Infection Testing in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Candida Infection Testing Industry Trends Table 2. Candida Infection Testing Industry Drivers Table 3. Candida Infection Testing Industry Opportunities and Challenges Table 4. Candida Infection Testing Industry Restraints Table 5. Global Candida Infection Testing Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Candida Infection Testing Revenue Share by Company (2021-2026) Table 7. Global Candida Infection Testing Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Candida Infection Testing Key Company Manufacturing Base & Headquarters Table 9. Global Candida Infection Testing Company, Product Type & Application Table 10. Global Candida Infection Testing Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Candida Infection Testing by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Traditional Culture Table 15. Significant Companies of Molecular Biology Detection Table 16. Global Candida Infection Testing Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Candida Infection Testing Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Candida Infection Testing Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Candida Infection Testing Sales Value Share by Type (2021-2026) Table 20. Global Candida Infection Testing Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Medical Table 22. Significant Companies of Maternal and Child Health Table 23. Significant Companies of Physical Examination Table 24. Significant Companies of Aesthetic Medicine Table 25. Significant Companies of Other Table 26. Global Candida Infection Testing Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Candida Infection Testing Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Candida Infection Testing Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Candida Infection Testing Sales Value Share by Application (2021-2026) Table 30. Global Candida Infection Testing Sales Value Share by Application (2027-2032) Table 31. Global Candida Infection Testing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Candida Infection Testing Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Candida Infection Testing Sales Value Share by Region (2021-2026) Table 34. Global Candida Infection Testing Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Candida Infection Testing Sales Value Share by Region (2027-2032) Table 36. Global Candida Infection Testing Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Candida Infection Testing Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Candida Infection Testing Sales Value Market Share by Country (2021-2026) Table 39. Global Candida Infection Testing Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Candida Infection Testing Sales Value Market Share by Country (2027-2032) Table 41. Roche Diagnostics Company Information Table 42. Roche Diagnostics Business Overview Table 43. Roche Diagnostics Candida Infection Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Roche Diagnostics Candida Infection Testing Product Portfolio Table 45. Roche Diagnostics Recent Development Table 46. Abbott Diagnostics Company Information Table 47. Abbott Diagnostics Business Overview Table 48. Abbott Diagnostics Candida Infection Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Abbott Diagnostics Candida Infection Testing Product Portfolio Table 50. Abbott Diagnostics Recent Development Table 51. bioMérieux Company Information Table 52. bioMérieux Business Overview Table 53. bioMérieux Candida Infection Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. bioMérieux Candida Infection Testing Product Portfolio Table 55. bioMérieux Recent Development Table 56. Becton Dickinson Company Information Table 57. Becton Dickinson Business Overview Table 58. Becton Dickinson Candida Infection Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Becton Dickinson Candida Infection Testing Product Portfolio Table 60. Becton Dickinson Recent Development Table 61. Thermo Fisher Scientific Company Information Table 62. Thermo Fisher Scientific Business Overview Table 63. Thermo Fisher Scientific Candida Infection Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Thermo Fisher Scientific Candida Infection Testing Product Portfolio Table 65. Thermo Fisher Scientific Recent Development Table 66. Siemens Healthineers Company Information Table 67. Siemens Healthineers Business Overview Table 68. Siemens Healthineers Candida Infection Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Siemens Healthineers Candida Infection Testing Product Portfolio Table 70. Siemens Healthineers Recent Development Table 71. Bruker Company Information Table 72. Bruker Business Overview Table 73. Bruker Candida Infection Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Bruker Candida Infection Testing Product Portfolio Table 75. Bruker Recent Development Table 76. Danaher Company Information Table 77. Danaher Business Overview Table 78. Danaher Candida Infection Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Danaher Candida Infection Testing Product Portfolio Table 80. Danaher Recent Development Table 81. QuidelOrtho Company Information Table 82. QuidelOrtho Business Overview Table 83. QuidelOrtho Candida Infection Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. QuidelOrtho Candida Infection Testing Product Portfolio Table 85. QuidelOrtho Recent Development Table 86. Luminex Company Information Table 87. Luminex Business Overview Table 88. Luminex Candida Infection Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Luminex Candida Infection Testing Product Portfolio Table 90. Luminex Recent Development Table 91. Hologic Company Information Table 92. Hologic Business Overview Table 93. Hologic Candida Infection Testing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Hologic Candida Infection Testing Product Portfolio Table 95. Hologic Recent Development Table 96. Sysmex Company Information Table 97. Sysmex Business Overview Table 98. Sysmex Candida Infection Testing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Sysmex Candida Infection Testing Product Portfolio Table 100. Sysmex Recent Development Table 101. Bio‑Rad Laboratories Company Information Table 102. Bio‑Rad Laboratories Business Overview Table 103. Bio‑Rad Laboratories Candida Infection Testing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Bio‑Rad Laboratories Candida Infection Testing Product Portfolio Table 105. Bio‑Rad Laboratories Recent Development Table 106. Cepheid Company Information Table 107. Cepheid Business Overview Table 108. Cepheid Candida Infection Testing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Cepheid Candida Infection Testing Product Portfolio Table 110. Cepheid Recent Development Table 111. Qiagen Company Information Table 112. Qiagen Business Overview Table 113. Qiagen Candida Infection Testing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. Qiagen Candida Infection Testing Product Portfolio Table 115. Qiagen Recent Development Table 116. ARUP Laboratories Company Information Table 117. ARUP Laboratories Business Overview Table 118. ARUP Laboratories Candida Infection Testing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. ARUP Laboratories Candida Infection Testing Product Portfolio Table 120. ARUP Laboratories Recent Development Table 121. Labcorp Company Information Table 122. Labcorp Business Overview Table 123. Labcorp Candida Infection Testing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 124. Labcorp Candida Infection Testing Product Portfolio Table 125. Labcorp Recent Development Table 126. Quest Diagnostics Company Information Table 127. Quest Diagnostics Business Overview Table 128. Quest Diagnostics Candida Infection Testing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 129. Quest Diagnostics Candida Infection Testing Product Portfolio Table 130. Quest Diagnostics Recent Development Table 131. Eurofins Scientific Company Information Table 132. Eurofins Scientific Business Overview Table 133. Eurofins Scientific Candida Infection Testing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 134. Eurofins Scientific Candida Infection Testing Product Portfolio Table 135. Eurofins Scientific Recent Development Table 136. Synlab Company Information Table 137. Synlab Business Overview Table 138. Synlab Candida Infection Testing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 139. Synlab Candida Infection Testing Product Portfolio Table 140. Synlab Recent Development Table 141. Research Programs/Design for This Report Table 142. Authors List of This Report Table 143. Secondary Sources Table 144. Primary Sources List of Figures Figure 1. Candida Infection Testing Product Image Figure 2. Global Candida Infection Testing Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Candida Infection Testing Market Size (2021-2032) & (US$ Million) Figure 4. Global Candida Infection Testing Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Traditional Culture Image Figure 8. Molecular Biology Detection Image Figure 9. Global Candida Infection Testing Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Candida Infection Testing Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Candida Infection Testing Sales Value Share by Type (2021-2032) Figure 12. Medical Image Figure 13. Maternal and Child Health Image Figure 14. Physical Examination Image Figure 15. Aesthetic Medicine Image Figure 16. Other Image Figure 17. Global Candida Infection Testing Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Candida Infection Testing Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Candida Infection Testing Sales Value Share by Application (2021-2032) Figure 20. Global Candida Infection Testing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Candida Infection Testing Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Candida Infection Testing Sales Value (2021-2032) & (US$ Million) Figure 23. North America Candida Infection Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Candida Infection Testing Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Candida Infection Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Candida Infection Testing Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Candida Infection Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Candida Infection Testing Sales Value (2021-2032) & (US$ Million) Figure 29. South America Candida Infection Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Candida Infection Testing Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Candida Infection Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Candida Infection Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Candida Infection Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Candida Infection Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Candida Infection Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Candida Infection Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Candida Infection Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Candida Infection Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Candida Infection Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Candida Infection Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Candida Infection Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Candida Infection Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Candida Infection Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Candida Infection Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Candida Infection Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Candida Infection Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Candida Infection Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Candida Infection Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Candida Infection Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Candida Infection Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Candida Infection Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Candida Infection Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Candida Infection Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Candida Infection Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Candida Infection Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Candida Infection Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Candida Infection Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Candida Infection Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Candida Infection Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Candida Infection Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Candida Infection Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Candida Infection Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Candida Infection Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Candida Infection Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Candida Infection Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Candida Infection Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Candida Infection Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Candida Infection Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Candida Infection Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Candida Infection Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Candida Infection Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Candida Infection Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Candida Infection Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Candida Infection Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Candida Infection Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Candida Infection Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Candida Infection Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Candida Infection Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Candida Infection Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Candida Infection Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Candida Infection Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Candida Infection Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Candida Infection Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Candida Infection Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Candida Infection Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Candida Infection Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Candida Infection Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Candida Infection Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Candida Infection Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Candida Infection Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Candida Infection Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Candida Infection Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Candida Infection Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Candida Infection Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Candida Infection Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Candida Infection Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Candida Infection Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Candida Infection Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Candida Infection Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Candida Infection Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Candida Infection Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Candida Infection Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Candida Infection Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Candida Infection Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Candida Infection Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Candida Infection Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Candida Infection Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Candida Infection Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Candida Infection Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Candida Infection Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Candida Infection Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Candida Infection Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Candida Infection Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Candida Infection Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Candida Infection Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Traditional Culture
  • Molecular Biology Detection
Applications
  • Medical
  • Maternal and Child Health
  • Physical Examination
  • Aesthetic Medicine
  • Other
Companies covered
  • Roche Diagnostics
  • Abbott Diagnostics
  • bioMérieux
  • Becton Dickinson
  • Thermo Fisher Scientific
  • Siemens Healthineers
  • Bruker
  • Danaher
  • QuidelOrtho
  • Luminex
  • Hologic
  • Sysmex
  • Bio‑Rad Laboratories
  • Cepheid
  • Qiagen
  • ARUP Laboratories
  • Labcorp
  • Quest Diagnostics
  • Eurofins Scientific
  • Synlab

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Candida Infection Testing Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Candida Infection Testing Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Candida Infection Testing Market Dynamics
  1. 2.1 Candida Infection Testing Industry Trends
  2. 2.2 Candida Infection Testing Industry Drivers
  3. 2.3 Candida Infection Testing Industry Opportunities and Challenges
  4. 2.4 Candida Infection Testing Industry Restraints
3 Candida Infection Testing Market by Company
  1. 3.1 Global Candida Infection Testing Company Revenue Ranking in 2025
  2. 3.2 Global Candida Infection Testing Revenue by Company (2021-2026)
  3. 3.3 Global Candida Infection Testing Company Ranking (2024-2026)
  4. 3.4 Global Candida Infection Testing Company Manufacturing Base and Headquarters
  5. 3.5 Global Candida Infection Testing Company Product Type and Application
  6. 3.6 Global Candida Infection Testing Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Candida Infection Testing Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Candida Infection Testing Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Candida Infection Testing Market by Type
  1. 4.1 Candida Infection Testing Type Introduction
  2. 4.1.1 Traditional Culture
  3. 4.1.2 Molecular Biology Detection
  4. 4.2 Global Candida Infection Testing Sales Value by Type
  5. 4.2.1 Global Candida Infection Testing Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Candida Infection Testing Sales Value by Type (2021-2032)
  7. 4.2.3 Global Candida Infection Testing Sales Value Share by Type (2021-2032)
5 Candida Infection Testing Market by Application
  1. 5.1 Candida Infection Testing Application Introduction
  2. 5.1.1 Medical
  3. 5.1.2 Maternal and Child Health
  4. 5.1.3 Physical Examination
  5. 5.1.4 Aesthetic Medicine
  6. 5.1.5 Other
  7. 5.2 Global Candida Infection Testing Sales Value by Application
  8. 5.2.1 Global Candida Infection Testing Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Candida Infection Testing Sales Value by Application (2021-2032)
  10. 5.2.3 Global Candida Infection Testing Sales Value Share by Application (2021-2032)
6 Candida Infection Testing Regional Value Analysis
  1. 6.1 Global Candida Infection Testing Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Candida Infection Testing Sales Value by Region (2021-2032)
  3. 6.2.1 Global Candida Infection Testing Sales Value by Region: 2021-2026
  4. 6.2.2 Global Candida Infection Testing Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Candida Infection Testing Sales Value (2021-2032)
  7. 6.3.2 North America Candida Infection Testing Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Candida Infection Testing Sales Value (2021-2032)
  10. 6.4.2 Europe Candida Infection Testing Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Candida Infection Testing Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Candida Infection Testing Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Candida Infection Testing Sales Value (2021-2032)
  16. 6.6.2 South America Candida Infection Testing Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Candida Infection Testing Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Candida Infection Testing Sales Value Share by Country, 2025 VS 2032
7 Candida Infection Testing Country-level Value Analysis
  1. 7.1 Global Candida Infection Testing Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Candida Infection Testing Sales Value by Country (2021-2032)
  3. 7.2.1 Global Candida Infection Testing Sales Value by Country (2021-2026)
  4. 7.2.2 Global Candida Infection Testing Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Candida Infection Testing Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Candida Infection Testing Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Candida Infection Testing Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Candida Infection Testing Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Candida Infection Testing Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Candida Infection Testing Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Candida Infection Testing Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Candida Infection Testing Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Candida Infection Testing Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Candida Infection Testing Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Candida Infection Testing Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Candida Infection Testing Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Candida Infection Testing Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Candida Infection Testing Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Candida Infection Testing Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Candida Infection Testing Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Candida Infection Testing Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Candida Infection Testing Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Candida Infection Testing Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Candida Infection Testing Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Candida Infection Testing Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Candida Infection Testing Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Candida Infection Testing Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Candida Infection Testing Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Candida Infection Testing Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Candida Infection Testing Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Candida Infection Testing Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Candida Infection Testing Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Candida Infection Testing Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Candida Infection Testing Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Candida Infection Testing Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Candida Infection Testing Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Candida Infection Testing Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Candida Infection Testing Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Candida Infection Testing Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Candida Infection Testing Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Candida Infection Testing Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Candida Infection Testing Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Candida Infection Testing Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Candida Infection Testing Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Candida Infection Testing Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Candida Infection Testing Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Candida Infection Testing Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Candida Infection Testing Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Candida Infection Testing Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Candida Infection Testing Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Candida Infection Testing Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Candida Infection Testing Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Candida Infection Testing Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Candida Infection Testing Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Candida Infection Testing Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Candida Infection Testing Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Candida Infection Testing Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Candida Infection Testing Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Candida Infection Testing Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Candida Infection Testing Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Candida Infection Testing Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Candida Infection Testing Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Candida Infection Testing Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Candida Infection Testing Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Candida Infection Testing Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Candida Infection Testing Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Candida Infection Testing Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Candida Infection Testing Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Candida Infection Testing Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Candida Infection Testing Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Candida Infection Testing Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Candida Infection Testing Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Candida Infection Testing Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Candida Infection Testing Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Candida Infection Testing Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Candida Infection Testing Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Candida Infection Testing Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Candida Infection Testing Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Candida Infection Testing Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Candida Infection Testing Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Candida Infection Testing Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Candida Infection Testing Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Candida Infection Testing Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Candida Infection Testing Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Candida Infection Testing Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Candida Infection Testing Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Candida Infection Testing Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Candida Infection Testing Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Roche Diagnostics
  2. 8.1.1 Roche Diagnostics Company Information
  3. 8.1.2 Roche Diagnostics Business Overview
  4. 8.1.3 Roche Diagnostics Candida Infection Testing Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Roche Diagnostics Candida Infection Testing Product Portfolio
  6. 8.1.5 Roche Diagnostics Recent Developments
  7. 8.2 Abbott Diagnostics
  8. 8.2.1 Abbott Diagnostics Company Information
  9. 8.2.2 Abbott Diagnostics Business Overview
  10. 8.2.3 Abbott Diagnostics Candida Infection Testing Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Abbott Diagnostics Candida Infection Testing Product Portfolio
  12. 8.2.5 Abbott Diagnostics Recent Developments
  13. 8.3 bioMérieux
  14. 8.3.1 bioMérieux Company Information
  15. 8.3.2 bioMérieux Business Overview
  16. 8.3.3 bioMérieux Candida Infection Testing Revenue and Gross Margin (2021-2026)
  17. 8.3.4 bioMérieux Candida Infection Testing Product Portfolio
  18. 8.3.5 bioMérieux Recent Developments
  19. 8.4 Becton Dickinson
  20. 8.4.1 Becton Dickinson Company Information
  21. 8.4.2 Becton Dickinson Business Overview
  22. 8.4.3 Becton Dickinson Candida Infection Testing Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Becton Dickinson Candida Infection Testing Product Portfolio
  24. 8.4.5 Becton Dickinson Recent Developments
  25. 8.5 Thermo Fisher Scientific
  26. 8.5.1 Thermo Fisher Scientific Company Information
  27. 8.5.2 Thermo Fisher Scientific Business Overview
  28. 8.5.3 Thermo Fisher Scientific Candida Infection Testing Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Thermo Fisher Scientific Candida Infection Testing Product Portfolio
  30. 8.5.5 Thermo Fisher Scientific Recent Developments
  31. 8.6 Siemens Healthineers
  32. 8.6.1 Siemens Healthineers Company Information
  33. 8.6.2 Siemens Healthineers Business Overview
  34. 8.6.3 Siemens Healthineers Candida Infection Testing Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Siemens Healthineers Candida Infection Testing Product Portfolio
  36. 8.6.5 Siemens Healthineers Recent Developments
  37. 8.7 Bruker
  38. 8.7.1 Bruker Company Information
  39. 8.7.2 Bruker Business Overview
  40. 8.7.3 Bruker Candida Infection Testing Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Bruker Candida Infection Testing Product Portfolio
  42. 8.7.5 Bruker Recent Developments
  43. 8.8 Danaher
  44. 8.8.1 Danaher Company Information
  45. 8.8.2 Danaher Business Overview
  46. 8.8.3 Danaher Candida Infection Testing Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Danaher Candida Infection Testing Product Portfolio
  48. 8.8.5 Danaher Recent Developments
  49. 8.9 QuidelOrtho
  50. 8.9.1 QuidelOrtho Company Information
  51. 8.9.2 QuidelOrtho Business Overview
  52. 8.9.3 QuidelOrtho Candida Infection Testing Revenue and Gross Margin (2021-2026)
  53. 8.9.4 QuidelOrtho Candida Infection Testing Product Portfolio
  54. 8.9.5 QuidelOrtho Recent Developments
  55. 8.10 Luminex
  56. 8.10.1 Luminex Company Information
  57. 8.10.2 Luminex Business Overview
  58. 8.10.3 Luminex Candida Infection Testing Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Luminex Candida Infection Testing Product Portfolio
  60. 8.10.5 Luminex Recent Developments
  61. 8.11 Hologic
  62. 8.11.1 Hologic Company Information
  63. 8.11.2 Hologic Business Overview
  64. 8.11.3 Hologic Candida Infection Testing Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Hologic Candida Infection Testing Product Portfolio
  66. 8.11.5 Hologic Recent Developments
  67. 8.12 Sysmex
  68. 8.12.1 Sysmex Company Information
  69. 8.12.2 Sysmex Business Overview
  70. 8.12.3 Sysmex Candida Infection Testing Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Sysmex Candida Infection Testing Product Portfolio
  72. 8.12.5 Sysmex Recent Developments
  73. 8.13 Bio‑Rad Laboratories
  74. 8.13.1 Bio‑Rad Laboratories Company Information
  75. 8.13.2 Bio‑Rad Laboratories Business Overview
  76. 8.13.3 Bio‑Rad Laboratories Candida Infection Testing Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Bio‑Rad Laboratories Candida Infection Testing Product Portfolio
  78. 8.13.5 Bio‑Rad Laboratories Recent Developments
  79. 8.14 Cepheid
  80. 8.14.1 Cepheid Company Information
  81. 8.14.2 Cepheid Business Overview
  82. 8.14.3 Cepheid Candida Infection Testing Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Cepheid Candida Infection Testing Product Portfolio
  84. 8.14.5 Cepheid Recent Developments
  85. 8.15 Qiagen
  86. 8.15.1 Qiagen Company Information
  87. 8.15.2 Qiagen Business Overview
  88. 8.15.3 Qiagen Candida Infection Testing Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Qiagen Candida Infection Testing Product Portfolio
  90. 8.15.5 Qiagen Recent Developments
  91. 8.16 ARUP Laboratories
  92. 8.16.1 ARUP Laboratories Company Information
  93. 8.16.2 ARUP Laboratories Business Overview
  94. 8.16.3 ARUP Laboratories Candida Infection Testing Revenue and Gross Margin (2021-2026)
  95. 8.16.4 ARUP Laboratories Candida Infection Testing Product Portfolio
  96. 8.16.5 ARUP Laboratories Recent Developments
  97. 8.17 Labcorp
  98. 8.17.1 Labcorp Company Information
  99. 8.17.2 Labcorp Business Overview
  100. 8.17.3 Labcorp Candida Infection Testing Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Labcorp Candida Infection Testing Product Portfolio
  102. 8.17.5 Labcorp Recent Developments
  103. 8.18 Quest Diagnostics
  104. 8.18.1 Quest Diagnostics Company Information
  105. 8.18.2 Quest Diagnostics Business Overview
  106. 8.18.3 Quest Diagnostics Candida Infection Testing Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Quest Diagnostics Candida Infection Testing Product Portfolio
  108. 8.18.5 Quest Diagnostics Recent Developments
  109. 8.19 Eurofins Scientific
  110. 8.19.1 Eurofins Scientific Company Information
  111. 8.19.2 Eurofins Scientific Business Overview
  112. 8.19.3 Eurofins Scientific Candida Infection Testing Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Eurofins Scientific Candida Infection Testing Product Portfolio
  114. 8.19.5 Eurofins Scientific Recent Developments
  115. 8.20 Synlab
  116. 8.20.1 Synlab Company Information
  117. 8.20.2 Synlab Business Overview
  118. 8.20.3 Synlab Candida Infection Testing Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Synlab Candida Infection Testing Product Portfolio
  120. 8.20.5 Synlab Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst